DOSELIA will use HARMONIC’s radiotherapy data to develop an AI-tool for precise evaluation of whole-body radiation doses delivered to each patient
Every year, 35,000 children and adolescents in Europe are diagnosed with cancer, with over 80% surviving at least five years. In 2020, Europe had approximately 600,000 survivors of paediatric cancer, a number expected to keep growing.
Radiotherapy is critical for treating childhood cancers, but it can have long-term risks, with one in five patients developing a second tumour before the age of 50.
An AI-tool for precision radiotherapy
“Current planning systems cannot accurately estimate radiation doses received by tissues far from the target organ, which complicates treatment planning and optimisation,” explains Charlotte Robert, researcher at Gustave Roussy Institute and coordinator of the European-funded DOSELIA project, recently launched.
DOSELIA aims to develop an AI-powered software tool for the precise evaluation of radiation doses delivered to the entire body during the patient’s care. It will also provide models to predict the the risk of secondary cancers in cured patients.
Importantly, DOSELIA will draw on data from HARMONIC’s registry of paediatric cancer patients. “Thanks to this collaboration, DOSELIA will be able to utilise a unique European database to train and validate its algorithms on real-life data, ensuring greater accuracy in dose estimations and risk projections for future patients,” says Neige Journy, who co-led HARMONIC’s Radiotherapy work package.
“Integrating this AI tool into routine clinical practice could help doctors optimise each treatment, reducing exposure of healthy tissue while maintaining maximum tumour control,” adds Robert.
For more information on DOSELIA, click here.